DailyIQ
|
Sector:Consumer DefensiveAll sectors
Last updated 4 minutes ago

KVUE·Kenvue Inc.

$.
+. (+.%)
After Hours
High
$19.08
Open
$18.93
Market Cap
36.44B
52W High
$22.87
Low
$18.89
P. Close
$19.03
P/E
22.47
52W Low
$14.02
Fwd P/E
59.59
DailyIQ Est.
$19.76
Technical Score (1D)
64
BUY
News Sentiment
55
BULLISH
UBS lifted its price target for Kenvue to $20 from $18 while keeping a neutral rating, signaling modest upside potential. The upgrade reflects confidence in the company’s growth prospects but acknowledges current valuation levels. Traders should monitor the upcoming earnings release for guidance updates and watch for regulatory approval of new product lines that could impact the valuation. A federal appeals court recently vacated a dismissal of claims linking Tylenol to autism, allowing the lawsuit to proceed against Kenvue. This development introduces potential liability and could increase legal expenses, which may weigh on short‑term earnings. Investors should watch how Kenvue addresses the litigation in the next earnings report and any settlement negotiations that may arise. HSBC also raised its target to $20 from $19, reinforcing a more optimistic view of the company’s product pipeline and market expansion. The combined analyst upgrades suggest that the market is pricing in a gradual upside, but the pending litigation remains a risk factor. In addition, the company is the target of a $48.7 billion acquisition bid by Kimberly‑Clark, which could provide a premium if regulatory clearance is obtained.
Earnings Summary
KVUE, a global consumer health company headquartered in Summit, New Jersey, markets a broad portfolio of well‑known over‑the‑counter and personal care brands such as Tylenol, Neutrogena, Johnson’s baby care, and Band‑Aid. Operating within the consumer defensive sector and the household & personal products industry, KVUE serves consumers worldwide with essential health and beauty solutions. In the most recent reporting cycle, KVUE posted EPS of $0.27 in Q4 2025 and $0.32 in Q1 2026, both surpassing analyst expectations of $0.2256 and $0.30627 respectively, while revenue climbed from $3.78 billion to $3.91 billion, a 3.4 % year‑over‑year gain. Compared to the prior two quarters—Q2 2025 EPS $0.29 and revenue $3.84 billion, Q3 2025 EPS $0.28 and revenue $3.76 billion—KVUE’s earnings trajectory shows a modest dip in Q4 followed by a stronger rebound in Q1 2026, and a revenue trend that has been largely upward with only a brief 2 % decline between Q2 and Q3. Historically, the company has consistently beaten EPS estimates in every quarter since 2024, with revenue growth maintained even when EPS missed in a single period, underscoring a resilient operating model. Recent analyst commentary highlights UBS and HSBC raising price targets to $20, reflecting confidence in KVUE’s product pipeline, while a federal appeals court has allowed autism‑related claims linked to Tylenol to proceed, potentially increasing legal expenses; the pending $48.7 billion acquisition bid by Kimberly‑Clark adds upside potential if regulatory approval is secured. Investors should watch for guidance updates in the next earnings release, any commentary on litigation costs or settlement progress, and developments in the acquisition process, as these factors will likely shape the company’s valuation trajectory in the coming quarters.

EPS

EstBeatMiss
$0.21$0.24$0.27$0.30$0.33Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.32 - -
Q1'26$0.31$0.32+4.5%
Q4'25$0.23$0.27+19.7%
Q3'25$0.26$0.28+5.7%
Q2'25$0.28$0.29+2.2%
Q1'25$0.23$0.24+5.4%

Revenue

EstBeatMiss
$3.7B$3.8B$3.9B$4.0B$4.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.0B - -
Q1'26$3.9B$3.9B-0.3%
Q4'25$3.8B$3.8B+0.7%
Q3'25 - $3.8B -
Q2'25 - $3.8B -
Q1'25 - $3.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

KVUE Stock Snapshot

KVUE is currently trading at $19.00, giving Kenvue Inc. a market cap of 36.44B and a P/E ratio of 22.5. Today's range spans $18.89–$19.08, with shares opening at $18.93 and moving down $0.03 (0.2%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD) with a news sentiment reading of 55/100.

Over the past year KVUE has traded between $14.02 and $22.87 - the current price is +35.5% off the 52-week low and -16.9% from the high. 22 analysts cover the stock with a Hold consensus and a mean 12-month target of $19.75 (range $18.00–$23.00), implying upside of +3.9%.

Kenvue Inc. (KVUE) is a large-cap in Consumer Defensive with 36.44B in market cap, currently sitting on a HOLD signal at 64/100. Price: $19.00 (in the middle of its 52-week range). Sentiment: neutral at 55/100. The current P/E ratio stands at 22.5. The 52-week range of $14.02–$22.87 is the structural anchor, and the current neutral phase is the market's way of asking for more information before committing to a direction.

Portfolio construction in Consumer Defensive often uses large-cap names like KVUE as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 64/100 (HOLD) at $19.00 (in the middle of its 52-week range) and neutral sentiment (55/100) frame the position as a catalyst play within the $14.02–$22.87 annual range rather than a directional bet.